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Abstract Oral isotretinoin is the most eVective choice in
the treatment of severe acne. Application of isotretionin to
acne has been expanded to treat those patients with less
severe but scarring acne who are responding unsatisfacto-
rily to conventional therapies. However, its use is associ-
ated with many side eVects, some of which can result in
very disastrous consequences. Data related with intermit-
tent isotretinoin therapy is still limited. Our aim was to
asses the eYcacy and tolerability of two diVerent intermit-
tent isotretinoin courses and compare them with conven-
tional isotretinoin treatment. In this multicenter and
controlled study, 66 patients with moderate to severe cases
were randomized to receive either isotretionin for the Wrst
10 days of each month for 6 months (group 1), or each day
in the Wrst month, afterwards the Wrst 10 days of each
month for 5 months (group 2) or daily for 6 months (group
3). The drug dosage was 0.5 mg/kg/day in all groups.
Patients were followed-up for 12 months. EYcacy values
were evaluable for 22 patients in group 1, 19 patients in
group 2, and 19 patients in group 3. Acne scores in each
group were signiWcantly lower at the end of treatment and
follow-up periods (P < 0.001). When patients were evalu-
ated separately as moderate (n = 31) and severe (n =2 9 ) ,  n o
statistically signiWcant diVerences were obtained among the
treatment protocols in patients with moderate acne. How-
ever, there was a signiWcant diVerence between groups 1
and 3 to the response of the treatments in severe acne
patients at the end of follow-up period (P = 0.013). The fre-
quency and severity of isotretionin-related side eVects were
found to be lower in groups 1 and 2 compared with group 3.
Intermittent isotretinoin may represent an eVective alterna-
tive treatment, especially in moderate acne with a low inci-
dence and severity of side eVects. The intermittent
isotretinoin can be recommended in those patients not toler-
ating the classical dosage.
Introduction
Oral isotretinoin is the most eVective choice in the treatment
of severe acne [7]. Acne especially in more severe forms has
the potential to result in scarring and permanent disWgure-
ment. Previous studies showed that combination therapies
are a highly eVective treatment in severe forms of acne.
However, scarring can occur in patients with acne who had
not responded to conventional antibiotic therapy and combi-
nation treatments [4]. This condition can cause signiWcant
embarrassment and anxiety when the aVected population is
considered. Therefore, eVective treatment is necessary to
prevent signiWcant psychological and social impairment in
these patients. Application of the drug to acne has been
expanded to treat those patients with less severe but scarring
acne who are responding unsatisfactorily to conventional
therapies [2, 5]. However, its use is associated with many
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side eVects, some of which can result in very disastrous con-
sequences. Because of the side eVects and the necessity of
long-term daily use of this drug, patients can have diYcul-
ties in complying with the treatment.
Recent reports indicate that acne patients have been bene-
Wting from the low dose or intermittent treatment protocols.
Low dose isotretinoin, such as 0.15–0.40 mg/kg was reported
to be eVective with a low incidence of severe side eVects [2,
7, 10]. Strauss et al. [11] showed that single daily doses of
0.4 mg/kg of micronized isotretinoin is eVective in patients
with severe recalcitrant nodular acne with a lower risk of
mucocutaneous events, and hypertriglyceridemia, than in
those receiving standard isotretinoin. Data related with inter-
mittent isotretinoin therapy is still limited. Goulden et al. [5]
and recently Kaymak et al. [6] in their open studies showed
that intermittent protocols are eVective in mild and moderate
acne with mild side-eVects. They administered isotretinoin
for 1 week in every 4 weeks for a total period of 6-month.
Goulden et al. [5] used the drug at a dosage of 0.5 mg/kg/day
and Kaymak et al. [6] at 0.5–0.75 mg/kg/day. These studies,
however, were not planned as controlled trials, and included
only mild to moderate acne cases. On the other hand, the
study of Kaymak et al. did not follow up the patients.
In the present multicenter, randomized and controlled
study, we aimed to asses the eYcacy and tolerability of two
diVerent intermittent isotretinoin courses and compare them
with conventional isotretinoin treatment. Besides moderate
cases, we also included severe cases in the study, and all
patients were followed-up for a period of 12-months.
Patients and methods
This was a multicenter, randomized and controlled study
consisting of 66 patients with the FDA global grade 2
(moderate) and 3–4 (severe) [3]. Patients with acne who
had not responded to conventional antibiotic therapy or
who had rapidly relapsed after conventional treatment were
included in the study. Patients were excluded if they had
acne conglobata, acne fulminans or systemic disorders
requiring any treatment. An appropriate washout period
before the treatment for patients who were receiving any
conventional treatments was applied before treatment
began. Patients in group 1 were treated for the Wrst 10 days
of each month for 6 months. Group 2 were given isotretin-
oin each day in the Wrst month, afterwards the Wrst 10 days
of each month for 5 months. In group 3, a conventional iso-
tretinoin treatment course was used for 6 months. Isotretin-
oin was administered at a dose of 0.5 mg/kg/day in all
groups (Fig.  1). Standard moisturizing and washing proce-
dures were recommended for each patient.
Facial lesions were taken into consideration. To evaluate
the FDA global grade, inXammatory (papules, pustules,
nodules), and non-inXammatory lesions (comedones) were
counted at each clinic visit by the same investigator in each
clinic. The FDA global grade was performed as previously
described [3]. The patients were examined clinically for
acne grading at the baseline, afterwards, every month dur-
ing therapy, and every 3 months for a 12-month follow-up
period.
During treatment, physicians recorded side eVects at
weeks 2, 4, 8, 12, 16, 20 and 24. Each side eVect was evalu-
ated on a 4-point scale as none (0), mild (1), moderate (2)
or severe (3). Side eVects were also scored by the patients
using a 10-cm visual anologue scale (VAS), ranging from
none to extremely noticable on a weekly basis during the
treatment.
Liver function tests and fasting lipids were evaluated at
the baseline, and afterwards, monthly during the treatment.
A pregnancy test was performed at the beginning, contra-
Fig. 1 Flow-chart of patients 
participating in the study. m/s 
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ceptive counselling was done during the treatment and the
Wrst 3 months of the follow-up period.
A repeated measure of ANOVA was used to test the
acne grading scores and side-eVect changes between the
study groups. Statistical analysis of the diVerence within
and between the study groups was carried out using the
Mann–Whitney U-test and Chi-squared with Fisher’s exact
test at the end of the 6-month treatment and 12-month fol-
low-up period.
Results
The study was completed on 22 patients in group 1
(19 female, 3 male; mean age § SD 22.7 § 5.5 years), 19
patients in group 2 (9 female, 10 male; mean age § SD
19.9 § 4.9 years) and 19 patients in group 3 (16 female, 3
male; mean age § SD 19.9 § 7.3 years). Six patients failed
to continue the follow-up (Fig. 1). Clinical data and total
dose of isotretinoin in each group are summarized in Table 1.
No statistically signiWcant diVerence was observed according
to age (P = 0.242) and gender (P = 0.228) among the groups.
The main objective of the study was to asses the eYcacy
and tolerability of the two diVerent intermittent isotretinoin
courses, and compare them with the conventional isotretin-
oin treatment. Our primary results were obtained at the end
of the treatment period (6 months). The clinical evaluation
for maintenance eYcacy of the treatments during the fol-
low-up period was the Wnal results.
The FDA global grade in each group was found to be
signiWcantly decreased compared with baseline values at
the end of treatment (P < 0.001). DiVerences were also sig-
niWcant in each group at the end of follow-up period
(P < 0.001). There were no statistically signiWcant diVer-
ences between the three treatment groups according to the
repeated measure of ANOVA (P = 0.554; Fig. 2).
However, when patients were evaluated according to the
FDA global grade, there was a statistically signiWcant
diVerence between groups 1 and 3 at the end of the 12-month
follow-up period (P = 0.002). The diVerence between
groups 2 and 3 was also close to the statistical signiWcance
(P = 0.053). In addition, only in group 1, 3 patients (14%) had
relapsed (emergence of pre-treatment acne scores) at the
end of the follow-up period; 2 had global grade 3 and 1 had
global grade 2.
When patients were divided into two groups, as moder-
ate and severe, there were no statistically signiWcant diVer-
ences among the treatment protocols in patients with
moderate acne at the end of the follow-up period (group 1
vs. 2, P = 0.5; group 2 vs. 3; P = 0.15; group 2 vs. 3,
P = 0.53). However, there was a statistically signiWcant
diVerence between groups 1 and 3 to the response of the
treatment at the end of the follow-up period in severe acne
patients (P = 0.013). The diVerence between groups 2 and 3
was not statistically signiWcant (P = 0.083; Fig. 3).
As presented in Table 2, the most common side eVects
were dry, chapped lips (73% in group 1, 95% in group 2,
100% in group 3) and dry skin (59% in group 1, 65% in
group 2, 78% in group 3) in all groups. Epistaxis (11%) and
fatigue (5%) were reported only in group 3. Hair loss, bone/
joint aches and pains, muscular cramps or pains were not
seen in any group. The frequency of all side eVects was
higher in group 3. The dryness in the mouth was signiW-
cantly higher in group 3 compared with the intermittent
groups (P = 0.001). The frequency of dry, chapped lips was
signiWcantly higher in groups 2 and 3 compared with group
1 (P = 0.015). The dryness of other mucosal tissues
(P = 0.044) and a rash or facial redness (P = 0.007) were
signiWcantly higher in group 3 compared with group 1.
Table 1 Clinical data and total dose of isotretinoin
Group 1 
(n =2 2 )
Group 2 
(n =1 9 )
Group 3 
(n =1 9 )
Age (year) 22.73 § 5.5 19.95 § 7.3 19.95 § 4.8
Sex
Female (n) (%) 14 (%63.6) 9 (%47.4) 14 (%73.7)
Male (n) (%) 8 (%36.4) 10 (%52.6) 5 (%26.3)
Mean total dose 
(mg/kg)
24.95 § 14.7 48.84 § 10.6 101.37 § 19.2
Fig. 2 The repeated measures of FDA global grades of two diVerent
intermittent isotretinoin and classical dosage. The graph reXects all in-
cluded patients. DiVerences in acne scores were not statistically signiW-
cant between the groups (0–18 months) according to the repeated
measure of ANOVA (P =0 . 5 5 4 )470 Arch Dermatol Res (2007) 299:467–473
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On the basis of data presented in Table 3, the severity
scale of all the side eVects recorded by physicians, were
found to be mild in intermittent groups. Although, the only
severity of dry, chapped lips was moderate (Fig. 4), other
side eVects were mild in group 3. The diVerences in dryness
in the mouth (P = 0.001), dry, chapped lips (P < 0.001),
dryness of other mucosal tissues (P = 0.026), a rash or
facial redness (P = 0.004), were statistically signiWcant
between intermittent groups and the classical dosage group.
The diVerences in pruritus (P = 0.064) and the peeling of
Wngertip skin (P = 0.056) were also close to the statistical
signiWcance.
Average VAS scores of side eVects (except for dry or
irritated eyes and excessive thirst) were signiWcantly higher
in group 3 compared with intermittent groups (Table 4).
Repeated measures of VAS for rash or facial redness pre-
sented in Fig. 5. VAS scores, in drug free intervals were
milder than on treatment days.
There were no signiWcant abnormalities between groups
in terms of liver function tests and fasting lipid values.
Discussion
In our study, both intermittent isotretinoin treatment
courses were found to be as eVective as classical dosage
during the treatment period with a low incidence and sever-
ity of side eVects. We did not obtain any signiWcant diVer-
ence among the treatment protocols in patients with
moderate acne. Goulden et al. [5] treated 80 patients with
chronic mild and moderate acne, resistant to conventional
treatments with isotretinoin (0.5 mg/kg/day), for 1 week in
every 4 weeks for a total period of 6 months. They reported
signiWcant reductions in acne scores. The treatment was
well tolerated with mild cheilitis noted as the only side
eVect. Twelve months following treatment, acne scores
remained signiWcantly improved compared with pre-treat-
ment values. In another open and uncontrolled study, Kay-
mak et al. [6] also used the same intermittent isotretinoin
protocol at a dosage of 0.5–0.75 mg/kg/day in 60 patients
with mild and moderate acne localized to the face. This
study did not have a follow-up period, and promising
results were also reported at the end of the treatment. Mild
side eVects were noted; however, their prevalence was
higher than the study of Goulden et al. [5] The diVerence
was explained by the higher dosages of isotretinoin used in
the study of Kaymak et al. In addition to previous intermit-
tent studies, we also included severe cases as well as mod-
erate acne patients. Due to this, we modiWed the previous
protocols, and increased the number of treatment days in
each month. Our results, in general, were consistent with
the previous two intermittent protocols, and may conWrm
the eVectiveness of this schedule. Additionally, we showed
that there was not a signiWcant diVerence between intermit-
tents and classical dosage treatments at the end of the
6-month treatment period.
When we evaluated the eVectiveness of treatment proto-
cols at the end of follow-up period, the decrease in acne
scores was statistically signiWcant in all groups. When we
investigated the diVerences among the groups, there was a
statistically signiWcant diVerence in the intermittent group 1
compared with the classical dosage group (group 3). On the
other hand, the diVerence between treatment groups 2 and 3
Fig. 3 DiVerences in FDA global grade for patients with moderate
acne (n = 31) a and severe acne (n =2 9 )   b at the end of follow-up pe-
riod. DiVerences between groups 1 and 3 in severe acne patients was
signiWcant (P = 0.013)Arch Dermatol Res (2007) 299:467–473 471
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was also close to the statistical signiWcance. When patients
were divided into two groups, as moderate and severe,
according to the severity of the disease, there was not a sig-
niWcant diVerence among the treatment protocols in moder-
ate acne patients at the end of the follow-up period.
However, there was a statistically signiWcant diVerence
between groups 1 and 3, for response of the treatments in
severe acne patients. In the study of Goulden et al. [5], acne
grades remained signiWcantly improved compared with pre-
treatment values at the end of the 12-month follow-up
period. However, 39% of the patients were reported as
relapsed. In our study, only 14% of patients from the inter-
mittent group 1 reached the pretreatment levels at the end
of the follow-up period. Another attribute of our patients in
the intermittent groups that diVer from the study of Goul-
den et al. (21 mg/kg) is that the patients in our study were
given a higher cumulative dosage during the treatment
(25 mg/kg in group 1 and 49 mg/kg in group 2). This may
explain the lower relapse rates, and again stress the impor-
tance of the cumulative dosages of isotretionin to prevent
relapses.
In our study, the frequency and severity of isotretionin-
related side eVects were found to be lower in group 1 and 2
compared with group 3. When side eVects were evaluated
according to treatment protocols, the frequency of side eVects
in respect to dryness in mucosal tissues, dry and chapped lips
and rash/facial redness were signiWcantly lower in both inter-
mittent groups compared to the patients receiving classical
Table 2 Frequency of side 
eVects recorded by physicians
Side eVects Group 1 n (%) Group 2 n (%) Group 3 n (%) P
Mucocutaneous
Dryness in mouth 2 (9) 1 (5) 9 (47) 0.001a
Dry, chapped lips 16 (73) 18 (95) 19 (100) 0.015b
Dry skin 13 (59) 13 (65) 14 (78) 0.451
Dry or irritated eyes 2 (9) 1 (5) 3 (16) 0.548
Dryness of other mucosal tissues 0 (0) 1 (5) 4 (21) 0.044c
Pruritus 3 (14) 3 (16) 6 (32) 0.307
Rash or facial redness 1 (5) 6 (32) 9 (47) 0.007
Epistaxis 0 (0) 0 (0) 2 (11) 0.107
Peeling of Wngertip skin 0 (0) 2 (11) 4 (21) 0.081
Other
Hair loss 0 (0) 0 (0) 0 (0) –
Bone/joint aches and pains 0 (0) 0 (0) 0 (0) –
Muscular cramps or pains 0 (0) 0 (0) 0 (0) –
Fatigue 0 (0) 0 (0) 1 (5) 0.334
Excessive thirst 2 (9) 4 (21) 3 (16) 0.561
a Between group 1–2 and group 3
b Between group 1 and group 2–3
c Between group 1 and group 3
Table 3 Average scores for 
side eVects recorded by 
physicians 
Side eVects Group 1 Group 2 Group 3 P
Mucocutaneous
Dryness in mouth 0.09 0.05 0.47 0.001
Dry, chapped lips 0.71 1.16 1.95 <0.001
Dry skin 0.59 0.67 0.76 0.461
Dry or irritated eyes 0.09 0.05 0.16 0.275
Dryness of other mucosal tissues 0.00 0.05 0.21 0.026
Pruritus 0.14 0.16 0.37 0.064
Rash or facial redness 0.05 0.32 0.47 0.004
Epistaxis 0.00 0.00 0.11 0.361
Peeling of Wngertip skin 0.00 0.11 0.32 0.056
Other
Fatigue 0.00 0.00 0.05 0.422
Excessive thirst 0.14 0.26 0.16 0.623
Side eVects were evaluated on a 
4-point scale as none (0), mild 
(1), moderate (2) or severe (3)472 Arch Dermatol Res (2007) 299:467–473
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dosage. Moreover, the severity scale of side eVects recorded
by physicians and average VAS scores of side eVects, were
also found to be milder in intermittent groups. In intermittent
groups, we observed a signiWcant decrease in the severity of
side eVects, especially in drug free intervals, which may
explain the increased compliance of these patients to the
treatment. Beside neglectable side eVects, the other important
issue is that the intermittent protocols have lower cost than
standard doses. Therefore, lower side eVects and treatment
cost could encourage patients to use isotretinoin.
Previous studies and our intermittent treatment protocols
clearly show the eVectiveness of these regimens, especially
in mild to moderate acne patients, with a reduced risk of
side eVects and increased patients compliance. In the light
of our results, we can recommend both intermittent isotreti-
onin protocols for those patients with moderate acne, unre-
sponsive to the antibiotic treatment, or who have a
tendency to the development of scars. Our study also
showed that intermittent treatment protocols were eVective
in decreasing acne scores in severe acne patients during the
treatment. However, we observed an increased rate of
recurrences in group 1 during the follow-up period. There-
fore, in severe cases, we only suggest intermittent isotretin-
oin treatment protocol 2 for those patients who do not
Fig. 4 Repeated measures of average severity scores for dry, chapped
lips (P < 0.001)
Table 4 Average visual 
analogue scale scores for side 
eVects
Side eVects Group 1 Group 2 Group 3 P
Mucocutaneous
Dryness in mouth 0.17 0.37 0.59 0.039
Dry, chapped lips 2.09 3.16 4.63 <0.001
Dry skin 1.23 1.68 2.32 0.011
Dry or irritated eyes 0.05 0.58 0.53 0.084
Dryness of other mucosal tissues 0.05 0.00 0.21 0.015
Pruritus 0.27 0.58 1.79 <0.001
Rash or facial redness 0.82 1.58 2.79 0.001
Epistaxis 0.00 0.00 0.16 0.005
Peeling of Wngertip skin 0.05 0.16 0.53 0.010
Other
Fatigue 0.00 0.00 0.58 0.002
Excessive thirst 0.00 0.05 0.32 0.206
Fig. 5 Repeated measures of VAS for rash or facial redness. DiVer-
ences in VAS were statistically signiWcant between group 3 and inter-
mittents groups (P = 0.001)Arch Dermatol Res (2007) 299:467–473 473
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tolerate the classical dosage. In patients who have a ten-
dency to increase in acne scores during the follow-up, a
new intermittent treatment course, or microdose isotretin-
oin can be started to reach the suYcient cumulative dosage.
In the literature, microdose isotretinoin (20–40 mg/weekly
equal to 0.04–0.11 mg/kg/day) had been tried to prevent the
relapse in adult patients suVering from relapse immediately
after standard isotretinoin protocol [1,9].
Our study also had some limitations. Because of the
study design, there were diVerent investigators, who might
have caused some diVerences in the evaluation of the
patients. Furthermore, the follow-up period (12 months)
was relatively short.
There is no doubt, that taking a drug at much shorter
courses, and lower total doses represents a major therapeu-
tic advance, increases patient compliance, and reduces the
risk of side eVects. Although oral isotretinoin is the most
eVective choice for severe acne, its use is associated with
many side eVects. In this respect, it is needless to say, that
intermittent use of isotretinoin may have many advanta-
geous. In our study, treatment of acne with two diVerent
intermittent courses was found to be eVective, especially in
moderate acne with a low incidence and severity of side
eVects. When the recurrence rates of intermittent courses
was evaluated, only intermittent treatment course 2 can be
recommended in those severe cases not tolerating the clas-
sical dosage. Our results may also indicate that intermittent
dose schedule and treatment duration require further evalu-
ation in severe acne, since we have observed a higher rate
of relapse compared with classical dosage.
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